|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/47 | (2006.01) |
| A61K 31/675 | (2006.01) | ||
| A61K 31/7048 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3338779 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16837150.8 |
| Date of filing the European patent application | 2016-08-18 | |
| (97) | Date of publication of the European application | 2018-06-27 |
| (45) | Date of publication and mention of the grant of the patent | 2021-06-30 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/JP2016/074090 |
| Date | 2016-08-18 |
| (87) | Number | WO 2017/030161 |
| Date | 2017-02-23 |
| (30) | Number | Date | Country code |
| 201562207546 P | 2015-08-20 | US |
| (72) |
OKAMOTO, Kiyoshi , JP
MATSUI, Junji , JP
DUTCUS, Corina , US
|
| (73) |
Eisai R&D Management Co., Ltd. ,
4-6-10 Koishikawa
Bunkyo-ku, Tokyo 112-8088,
JP
|
| (54) | LENVATINIB IN COMBINATION WITH ETOPOSIDE AND IFOSFAMIDE FOR USE IN TREATING A TUMOR |
| LENVATINIB IN COMBINATION WITH ETOPOSIDE AND IFOSFAMIDE FOR USE IN TREATING A TUMOR |